# A Study of MDX-010 (BMS-734016) Administered With or Without Prophylactic Oral Budesonide

> **NCT00135408** · PHASE2 · COMPLETED · sponsor: **Bristol-Myers Squibb** · enrollment: 115 (actual)

## Conditions studied

- Malignant Melanoma

## Interventions

- **DRUG:** Ipilimumab+ Placebo
- **DRUG:** Ipilimumab+ Budesonide

## Key facts

- **NCT ID:** NCT00135408
- **Lead sponsor:** Bristol-Myers Squibb
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-12
- **Primary completion:** 2007-07
- **Final completion:** 2007-07
- **Target enrollment:** 115 (ACTUAL)
- **Last updated:** 2016-09-28

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00135408

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00135408, "A Study of MDX-010 (BMS-734016) Administered With or Without Prophylactic Oral Budesonide". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00135408. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*